Learn About Processing Deficient Progeroid Laminopathies (PDPL)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Processing Deficient Progeroid Laminopathies (PDPL) Local Doctors?
Learn about our expert tiers
Learn more
What are the Latest Advances for Processing Deficient Progeroid Laminopathies (PDPL)?

There is no recent research available for this condition. Please check back because thousands of new papers are published every week and we strive to find and display the most recent relevant research as soon as it is available.

What are the latest Processing Deficient Progeroid Laminopathies (PDPL) Clinical Trials?
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
Summary: This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth progeria). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the...
Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies
Summary: Hutchinson-Gilford Progeria Syndrome (Progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise. The mutation for this disease has been identified and results in a mutant form of lamin A that cannot be de-farnesylated. This study evaluates the combination of pravastain (a statin), lonafarnib (a farnesyltr...